Clinical trial · Observational
Special Drug Use-results Surveillance of Scemblix Tablets
Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401)
NCT05421091CI-TRIAL-00075456completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Asciminib | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Asciminib
- description
- Patients prescribed with Asciminib
- interventionNames
- Other: Asciminib
Primary outcomes (4)
- measure
- Type, frequency, seriousness and severity of adverse event (AE)/treatment-related AE of the safety specifications
- timeFrame
- Up to 48 Weeks
- description
- For the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity), type, frequency AE, seriousness, severity of adverse event (AE)/treatment-related AE will be collected
- measure
- AEs leading to interruption/discontinuation of the safety specifications
- timeFrame
- Up to 48 Weeks
- description
- For the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity), AEs leading to interruption/discontinuation will be collected
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * patients treated with asciminib in Japan. Exclusion Criteria: NA
References
Publications (0)
Data not yet available
No reference posted for this study.